Table 2.
Analysis of the association between DNA repaired gene polymorphisms and response to cisplatin-based chemotherapy in osteosarcoma patients
| Genotypes | Good response N = 133 | % | Poor response N = 81 | % | Adjusted OR (95% CI)1 | P value |
|---|---|---|---|---|---|---|
| ERCC1 rs11615 | ||||||
| TT | 52 | 38.83 | 41 | 50.82 | 1.0 (Ref.) | - |
| TC | 54 | 40.78 | 31 | 37.70 | 1.37 (0.72-2.62) | 0.31 |
| CC | 27 | 20.39 | 9 | 11.48 | 2.51 (1.02-6.85) | 0.03 |
| ERCC2 rs1799793 | ||||||
| GG | 74 | 55.34 | 54 | 67.21 | 1.0 (Ref.) | - |
| GA | 39 | 29.13 | 20 | 24.59 | 1.42 (0.72-2.87) | 0.28 |
| AA | 21 | 15.53 | 7 | 8.20 | 2.19 (0.82-6.52) | 0.09 |
| ERCC2 rs13181 | ||||||
| AA | 76 | 57.28 | 49 | 60.66 | 1.0 (Ref.) | - |
| AC | 41 | 31.07 | 24 | 29.51 | 1.10 (0.57-2.15) | 0.76 |
| CC | 15 | 11.65 | 8 | 9.84 | 1.21 (0.44-3.55) | 0.69 |
| NBN rs709816 | ||||||
| GG | 47 | 35.34 | 33 | 40.98 | 1.0 (Ref.) | - |
| GC | 56 | 41.75 | 32 | 39.34 | 1.22 (0.63-2.40) | 0.52 |
| CC | 30 | 22.91 | 16 | 19.67 | 1.32 (0.58-3.02) | 0.47 |
| RAD51 rs1801320 | ||||||
| GG | 62 | 46.60 | 41 | 50.82 | 1.0 (Ref.) | - |
| GC | 56 | 41.75 | 31 | 37.70 | 1.19 (0.64-2.25) | 0.55 |
| CC | 15 | 11.65 | 9 | 11.48 | 1.10 (0.41-3.14) | 0.84 |
| XRCC3 rs861539 | ||||||
| CC | 63 | 47.57 | 42 | 52.46 | 1.0 (Ref.) | - |
| CT | 57 | 42.72 | 33 | 40.98 | 1.15 (0.62-2.15) | 0.63 |
| TT | 13 | 9.71 | 5 | 6.56 | 1.73 (0.53-6.65) | 0.32 |
1
Ajusted for age, tumor size, clinical stage, lymph mode metastasis and ER and PR status.